



Universiteit
Leiden
The Netherlands

Clinical pharmacology of the tyrosine kinase inhibitors imatinib and sunitinib

Erp, P.H. van

Citation

Erp, P. H. van. (2009, December 16). *Clinical pharmacology of the tyrosine kinase inhibitors imatinib and sunitinib*. Retrieved from <https://hdl.handle.net/1887/14515>

Version: Corrected Publisher's Version

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/14515>

Note: To cite this publication please use the final published version (if applicable).

Clinical Pharmacology of the Tyrosine Kinase Inhibitors Imatinib and Sunitinib

Nielka van Erp

Clinical Pharmacology of the Tyrosine Kinase Inhibitors Imatinib and Sunitinib

Proefschrift

ter verkrijging van
de graad Doctor aan de Universiteit Leiden,
op gezag van Rector Magnificus prof. mr. P.F. van der Heijden,
volgens besluit van het College voor Promoties
ter verdedigen op woensdag 16 december 2009
klokke 13:45 uur

door

Petronella Hubertha van Erp

geboren te Liempde
in 1977

The research presented in this thesis was performed at the Department of Clinical Pharmacy
and Toxicology of Leiden University Medical Center, The Netherlands.

Publication of this thesis was sponsored by:
AZL Onderzoeks- en Ontwikkelingskrediet (OOK) Apotheek
Koninklijke Nederlandse Maatschappij ter Bevordering der Pharmacie (KNMP)

Cover design and layout by: In Zicht Grafisch Ontwerp, Arnhem, www.promotie-inzicht.nl
Printed by: Ipskamp Drukkers, Enschede

ISBN 978-90-9024737-3

© P.H. van Erp 2009

All rights reserved. No parts of this publication may be reproduced, stored in a retrieval
system of any nature, or transmitted in any form or by any means, electronic, mechanical,
photocopying, recording or otherwise, without prior written permission of the publisher.

Promotor

Prof. Dr. H.-J. Guchelaar

Copromotor

Dr. A.J. Gelderblom

Overige leden

Prof. Dr. M. Danhof

Prof. Dr. H.M.W. Verheul, *Vrije Universiteit, Amsterdam*

Prof. Dr. J.H. Beijnen, *Universiteit Utrecht*

Dr. A. Sparreboom, *St. Jude Children's Research Hospital, Memphis, USA*

"Nothing in life is to be feared, it is only to be understood"
Marie Curie

Contents

1	General introduction	9
2	Clinical pharmacokinetics of tyrosine kinase inhibitors <i>Cancer Treatment Reviews 2009 (in press)</i>	17
Part 1 Clinical Pharmacology of Imatinib		53
3	Influence of CYP3A4 inhibition on the steady-state pharmacokinetics of imatinib <i>Clinical Cancer Research 2007; 13(24):7394-7400</i>	55
4	Effect of cigarette smoking on pharmacokinetics, safety and efficacy of imatinib: a study based on data of the Soft Tissue and Bone Sarcoma Group of the EORTC <i>Clinical Cancer Research 2008; 14(24):8308-8313</i>	73
5	Is rectal administration of imatinib an alternative route for imatinib? <i>Cancer Chemotherapy and Pharmacology 2007; 60(4):623-624</i>	89
Part 2 Clinical Pharmacology of Sunitinib		95
6	Relationship between CYP3A4 phenotyping and sunitinib exposure in cancer patients	97
7	Pharmacogenetic pathway analysis for determination of sunitinib-induced toxicity <i>Journal of Clinical Oncology 2009 (published online ahead of print, August 10, 2009)</i>	111
8	Clinically irrelevant effect of grapefruit juice on the steady-state sunitinib exposure <i>Submitted</i>	131
9	Mitotane has a strong inducing effect on CYP3A4 activity <i>Submitted</i>	149
10	Absorption of cytochrome P450 3A4 inhibiting furanocoumarins from grapefruit juice after oral administration <i>Submitted</i>	159
Part 3 Appendix		171
11	General Discussion and Future Perspectives	173
	Summary	185
	Nederlandse samenvatting	193
	Dankwoord	203
	List of Publications	205
	Curriculum Vitae	207